Test description
The fluoropyrimidines drugs, 5-fluorouracil (5-FU) and capecitabine, are widely used as chemotherapeutic agents in the treatment of solid tumours, including colorectal cancer, breast cancer and cancers of the upper gastrointestinal tract. Inherited genetic variants that result in reduced activity of the enzyme dihydropyrimidine dehydrogenase (DPD) are associated with increased treatment induced toxicity and increase an individual’s risk of experiencing potentially life-threatening complications including bone marrow suppression, gastrointestinal toxicity, and neurotoxicity.
Test information
DPYD Test
DPYD genetic testing identifies patients who are at risk of developing fluoropyrimidine toxicity and should receive reduced doses or avoid treatment with these drugs.
c.1905+1G>A, c.1679T>G, c.2846A>T, c.1129-5923C>G, c.557A>G, c.868A>G, c.2279C>T, c.299_302del, c.703C>T, c.1314T>G, c.1475C>T, c.1744C>T, c.2639G>T
MicroARRAY
5 days
73322 – criteria apply
If not MBS eligible, please contact 1800 822 999 for pricing details
Standard pathology request form
Blood
6mL EDTA Tube
None